Can Albumin-Globulin Ratio Predict Disease Progression in Diabetic Patients with NAFLD?

Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common cause of chronic liver disease globally, with an increasing prevalence among patients with type 2 diabetes mellitus (T2DM). The coexistence of NAFLD and diabetes accelerates liver fibrosis progression, increasing the risk of cirrhosis, hepatocellular carcinoma, and cardiovascular complications. Given the silent progression of NAFLD, early identification of high-risk individuals remains a clinical challenge.